{"id":"https://openalex.org/W4248937293","doi":"https://doi.org/10.1097/00002826-200001000-00007","title":"A Randomized Controlled Trial Comparing Pramipexole with Levodopa in Early Parkinson's Disease: Design and Methods of the CALM-PD Study","display_name":"A Randomized Controlled Trial Comparing Pramipexole with Levodopa in Early Parkinson's Disease: Design and Methods of the CALM-PD Study","alternate_titles":[],"publication_year":2000,"publication_date":"2000-01-01","ids":{"openalex":"https://openalex.org/W4248937293","doi":"https://doi.org/10.1097/00002826-200001000-00007","pmid":"https://pubmed.ncbi.nlm.nih.gov/10682229"},"language":"en","primary_location":{"id":"doi:10.1097/00002826-200001000-00007","doi":"https://doi.org/10.1097/00002826-200001000-00007","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00002826-200001000-00007","pdf_url":null,"source":{"id":"https://openalex.org/S3349026","display_name":"Clinical Neuropharmacology","issn_l":"0362-5664","issn":["0362-5664","1537-162X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Neuropharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4248937293"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5023314663","display_name":"Parkinson Study Group","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I28792581","display_name":"University of Rochester Medicine","ror":"https://ror.org/00trqv719","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I28792581","https://openalex.org/I5388228"]},{"id":"https://openalex.org/I4405267734","display_name":"Parkinson Study Group","ror":"https://ror.org/043gc8k06","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4405267734"]},{"id":"https://openalex.org/I5388228","display_name":"University of Rochester","ror":"https://ror.org/022kthw22","country_code":"US","type":"education","lineage":["https://openalex.org/I5388228"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Parkinson Study Group","raw_affiliation_strings":["A list of the members of the Parkinson Study Group is given at the end of this article","and reprint requests to Robert Holloway, Department of Neurology, University of Rochester, 1351 Mt. Hope Avenue, Suite 220, Rochester, NY 14620, USA","reprint requests to Robert Holloway, Department of Neurology, University of Rochester, 1351 Mt. Hope Avenue, Suite 220, Rochester, NY 14620, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"A list of the members of the Parkinson Study Group is given at the end of this article","institution_ids":["https://openalex.org/I4405267734"]},{"raw_affiliation_string":"and reprint requests to Robert Holloway, Department of Neurology, University of Rochester, 1351 Mt. Hope Avenue, Suite 220, Rochester, NY 14620, USA","institution_ids":["https://openalex.org/I28792581","https://openalex.org/I5388228"]},{"raw_affiliation_string":"reprint requests to Robert Holloway, Department of Neurology, University of Rochester, 1351 Mt. Hope Avenue, Suite 220, Rochester, NY 14620, USA","institution_ids":["https://openalex.org/I28792581","https://openalex.org/I5388228"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5023314663"],"corresponding_institution_ids":["https://openalex.org/I28792581","https://openalex.org/I4405267734","https://openalex.org/I5388228"],"apc_list":null,"apc_paid":null,"fwci":2.1195,"has_fulltext":false,"cited_by_count":132,"citation_normalized_percentile":{"value":0.86009642,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"23","issue":"1","first_page":"34","last_page":"44"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10919","display_name":"Deep Brain Stimulation and Movement Disorders","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13991","display_name":"Nuclear Receptors and Signaling","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pramipexole","display_name":"pramipexole","score":0.9549999833106995},{"id":"https://openalex.org/keywords/levodopa","display_name":"levodopa","score":1.0},{"id":"https://openalex.org/keywords/parkinson-s-disease","display_name":"Parkinson's disease","score":0.906000018119812},{"id":"https://openalex.org/keywords/early-parkinson-s-disease","display_name":"early-stage Parkinson's disease","score":0.8849999904632568},{"id":"https://openalex.org/keywords/wearing-off-phenomenon","display_name":"wearing-off phenomenon","score":0.8130000233650208},{"id":"https://openalex.org/keywords/dyskinesia","display_name":"dyskinesia","score":0.9549999833106995},{"id":"https://openalex.org/keywords/on-off-effect","display_name":"on-off effect","score":0.7390000224113464},{"id":"https://openalex.org/keywords/dopamine-agonists","display_name":"dopamine agonists","score":0.8080000281333923},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.8629999756813049},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.5809999704360962},{"id":"https://openalex.org/keywords/functional-imaging","display_name":"functional imaging","score":0.4480000138282776}],"concepts":[{"id":"https://openalex.org/C2779989193","wikidata":"https://www.wikidata.org/wiki/Q421304","display_name":"Pramipexole","level":4,"score":0.9868772029876709},{"id":"https://openalex.org/C2780304432","wikidata":"https://www.wikidata.org/wiki/Q300989","display_name":"Levodopa","level":4,"score":0.897475004196167},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7034609317779541},{"id":"https://openalex.org/C2779734285","wikidata":"https://www.wikidata.org/wiki/Q11085","display_name":"Parkinson's disease","level":3,"score":0.6586242318153381},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6416416764259338},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.5721989870071411},{"id":"https://openalex.org/C2776976799","wikidata":"https://www.wikidata.org/wiki/Q416444","display_name":"Entacapone","level":5,"score":0.5281227231025696},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5184707045555115},{"id":"https://openalex.org/C137183658","wikidata":"https://www.wikidata.org/wiki/Q461076","display_name":"Dopaminergic","level":3,"score":0.4768439531326294},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.45845144987106323},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.32637208700180054},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.31452101469039917},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.23468062281608582},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.19735699892044067},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.19233793020248413},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000077487","descriptor_name":"Pramipexole","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000978","descriptor_name":"Antiparkinson Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007980","descriptor_name":"Levodopa","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010300","descriptor_name":"Parkinson Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010300","descriptor_name":"Parkinson Disease","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D010300","descriptor_name":"Parkinson Disease","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D010300","descriptor_name":"Parkinson Disease","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015899","descriptor_name":"Tomography, Emission-Computed, Single-Photon","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018491","descriptor_name":"Dopamine Agonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D052160","descriptor_name":"Benzothiazoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/00002826-200001000-00007","doi":"https://doi.org/10.1097/00002826-200001000-00007","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00002826-200001000-00007","pdf_url":null,"source":{"id":"https://openalex.org/S3349026","display_name":"Clinical Neuropharmacology","issn_l":"0362-5664","issn":["0362-5664","1537-162X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Neuropharmacology","raw_type":"journal-article"},{"id":"pmid:10682229","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10682229","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical neuropharmacology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[{"id":"https://openalex.org/G3493866547","display_name":"General Clinical Research Center","funder_award_id":"M01RR001066","funder_id":"https://openalex.org/F4320337375","funder_display_name":"National Center for Research Resources"},{"id":"https://openalex.org/G426531767","display_name":"General Clinical Research Center","funder_award_id":"M01RR000044","funder_id":"https://openalex.org/F4320337375","funder_display_name":"National Center for Research Resources"}],"funders":[{"id":"https://openalex.org/F4320337375","display_name":"National Center for Research Resources","ror":"https://ror.org/04pw6fb54"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4239875825","https://openalex.org/W4230194219","https://openalex.org/W2563241409","https://openalex.org/W2028656651","https://openalex.org/W2077145474","https://openalex.org/W4234079360","https://openalex.org/W3163775459","https://openalex.org/W1582037413","https://openalex.org/W105182508","https://openalex.org/W2016533892"],"abstract_inverted_index":{"CALM-PD":[0,73],"(Comparison":[1],"of":[2,11,27,30,35,50,167],"the":[3,25,33,48,139,164],"agonist":[4],"pramipexole":[5,31,79,86],"with":[6,32,38,45,132],"levodopa":[7,39,82],"on":[8],"motor":[9,52,108],"complications":[10,109],"Parkinson's":[12,43],"disease)":[13],"is":[14],"a":[15,99],"randomized,":[16],"multicenter,":[17],"double-blind,":[18],"controlled":[19],"clinical":[20,150,157],"trial":[21],"designed":[22],"to":[23,47,66,76,102,147,153,162],"compare":[24],"policy":[26,34],"initial":[28,36],"treatment":[29,37],"in":[40,72,129],"early,":[41],"symptomatic":[42],"disease":[44],"regard":[46],"development":[49],"dopaminergic":[51,107],"complications.":[53],"At":[54],"22":[55],"American":[56],"and":[57,74,80,87,105,122,135,152,160],"Canadian":[58],"sites,":[59],"301":[60],"eligible":[61],"subjects":[62],"requiring":[63],"antiparkinsonian":[64],"therapy":[65],"treat":[67],"emerging":[68],"disability":[69],"were":[70],"enrolled":[71],"randomized":[75],"(i)":[77],"active":[78,88],"placebo":[81,85],"or":[83],"(ii)":[84],"levodopa.":[89],"Subjects":[90],"are":[91,126],"being":[92,127],"evaluated":[93],"systematically":[94],"at":[95],"regular":[96],"intervals":[97],"during":[98],"23.5-month":[100],"period":[101],"determine":[103],"if":[104],"when":[106],"(wearing":[110],"off,":[111],"dyskinesias,":[112],"\"on-off\"":[113],"effects)":[114],"occur.":[115],"In":[116],"addition,":[117],"quality-of-life":[118],"outcomes,":[119,121],"economic":[120],"functional":[123],"imaging":[124,137],"outcomes":[125],"assessed":[128],"standard":[130],"fashion":[131],"[123I]":[133],"beta-CIT":[134],"SPECT":[136],"throughout":[138],"trial.":[140],"The":[141],"study":[142],"design":[143],"contains":[144],"many":[145],"provisions":[146],"approximate":[148],"routine":[149],"practice":[151,166],"produce":[154],"data":[155],"about":[156],"effectiveness,":[158],"tolerability,":[159],"cost":[161],"facilitate":[163],"evidence-based":[165],"neurology.":[168]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4248937293","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":3},{"year":2019,"cited_by_count":10},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":6},{"year":2013,"cited_by_count":9},{"year":2012,"cited_by_count":7}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2022-05-12T00:00:00"}
